Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

The U.S. Food and Drug Administration recently approved a new class of non-opioid painkiller which one Lowcountry pharmacist is calling “revolutionary.” ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Trump during his address to Congress said that Canada and Mexico ‘have allowed fentanyl to come into our country at levels ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...